search
Back to results

Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment (TIPS)

Primary Purpose

Subjective Cognitive Impairment

Status
Not yet recruiting
Phase
Not Applicable
Locations
China
Study Type
Interventional
Intervention
Tai chi training
Group activity
Sponsored by
Ruijin Hospital
About
Eligibility
Locations
Arms
Outcomes
Full info

About this trial

This is an interventional prevention trial for Subjective Cognitive Impairment focused on measuring subjective cognitive impairment, Tai Chi

Eligibility Criteria

60 Years - 75 Years (Adult, Older Adult)All SexesDoes not accept healthy volunteers

Inclusion Criteria:

  1. Male and female participants aged 60 to 75 years (inclusive) at the time of screening;
  2. Willing and able to give informed consent by GCP and local guidance;
  3. Meets the diagnostic criteria for subjective cognitive impairment (SCI) and the following criteria

    • Subjective decline in memory, rather than other domains of cognition
    • Onset of SCI within the last 5 y
    • Concerns (worries) associated with SCI
    • Feeling of worse performance than others of the same age group
    • Confirmation of cognitive decline by an informant.
  4. Have the physical, cognitive, listening, speech, literacy and language skills necessary to participate in all tests;
  5. Capable of performing MR.

Exclusion Criteria:

  1. Cognitive impairment caused by other reasons (for example) cerebrovascular disease, central nervous system infection, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, dementia with Lewy bodies, trauma, other physical and chemical factors (drugs, alcohol, CO, etc.), important physical diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), brain tumor, endocrine diseases (thyroid disease, parathyroid disease), and vitamin deficiency or any other cause of dementia;
  2. Abnormal folate, thyroid, and/or vitamin B12 values that cannot be corrected before baseline visit;
  3. Major structural brain disease as judged by central MRI Diagnostic Imaging Review Team (eg, ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions. or a single lesion in a critical region [eg, thalamus]). Mild white matter changes without clinical significance and no more than 2 lacunar infarcts are permitted;
  4. Geriatric Depression Scale-15(GDS-15) total score > 7 at screening;
  5. MOCA<26 points;
  6. CDR global score >0;
  7. Hachinski ischemia score >4;
  8. During the clinical study, the following drugs are prohibited:

    Acetylcholinesterase inhibitors, N-methyl-D-aspartate (NMDA) antagonists (eg, memantine), central nervous system stimulants, and various medicines that can improve memory or cognition; Antipsychotics

  9. Mental illness determined by Diagnostic and Statistical Manual of Mental Disorders (DSM) V criteria, that is unstable within 12 months, or would interfere with study assessments, including schizophrenia or other psychotic disorders, bipolar disorder, severe depression, or delirium.
  10. DSM V diagnosis of alcohol or other substance abuse dependence within the last 12 months.
  11. History or current diagnosis of significant cardiac arrhythmias, myocardial infarction, transient ischemic attack, or cerebrovascular accident, uncompensated congestive heart failure New York Heart Association class III and IV.
  12. Major medical illness or unstable medical condition within 6 months of screening that in the opinion of the investigator may interfere with the participant's ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data, including any physical disability (eg. blindness. deafness, non-cognitive related speech impairment, sensory or motor dysfunction) that would prevent completion of study procedures or assessments.
  13. Cancer except:

    History of any cancer that has been in remission (no evidence of recurrence) for > 5 years from the screening Participants with basal cell or stage I squamous cell carcinoma of the skin, stable untreated cancer as prostate or meningioma.

  14. Active physical activity for 6 months prior to screening.
  15. Participants are excluded if they

    1. have participated in any other clinical study within 4 weeks prior to screening visit
    2. have participated in another Tai chi clinical study at any time
    3. plan to take part in another clinical study during this study.
  16. The researcher estimates that the subject's compliance is poor, and it is believed that the subject is unlikely to complete the study.

Sites / Locations

  • Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital

Arms of the Study

Arm 1

Arm 2

Arm Type

Experimental

Experimental

Arm Label

Tai chi training plus group activity

Only group activity

Arm Description

Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction. Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.

Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.

Outcomes

Primary Outcome Measures

The global cognitive function of SCI subjects.
Repeatable Battery for the Assessment of Neuropsychological Status(RBANS) will be used to assess the global cognitive performance of SCI subjects.

Secondary Outcome Measures

Memory
Memory will be assessed using the Auditory verbal learning test-Huashan version (AVLT-H).
Attention
Attention will be evaluated by Trial Making Test (TMT).
Executive function
Executive function will be evaluated by the Stroop task.
Language
Language will be assessed by Boston naming test (30-item version), and Verbal Fluency.
Working memory test
Working memory test will be assessed by Number Span Forward and Backward.
Visual spatial ability
Visual spatial ability will be assessed by Clock Drawing Test.
Change from baseline in MoCA score
Change from baseline in Montreal Cognitive Assessment (MoCA) score.
Change from baseline in CDR score
Change from baseline in Clinical Dementia Rating (CDR) Scale score.
Activities of daily living
Activities of daily living will be assessed by functional activities questionnaire (FAQ).
Anxiety
Anxiety will be assessed by Hamilton Anxiety Rating Scale (HAMA).
Depression
Depression will be assessed by Hamilton Depression Rating Scale (HAMD).
Sleep
Sleep will be assessed by Pittsburgh Sleep Quality Index (PSQI).
Brain activity
Detecting changes associated with blood flow by fMRI.
Neurodegeneration in brain structures
Brain atrophy will be assessed by Magnetic Resonance Volume Imaging.
Gut microbiota
Gut microbiota will be assessed by 16S rRNA sequencing.
Blood biomarkers
Inflammatory factors (FGF basic、Eotaxin、G-CSF、GM-CSF、IFN-γ、IL-1β、IL-1ra、IL-2、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-12 (p70)、IL-13、IL-15、IL-17、IP-10、MCP-1 (MCAF)、MIP-1α、MIP-1β、PDGF-BB、RANTES、TNF-α、VEGF) will be measured by Bio-Plex Human Cytokine Assays. Nfl, Aβ40, Aβ42,T-tau, p-tau
Gait and Hand writing Task
Using wearable sensors to assess gait and hand writing task.
Incidence of SCI converted to MCI and Alzheimer's disease.
The 3-year incidence of MCI and AD in each group will be compared.

Full Information

First Posted
July 28, 2022
Last Updated
July 30, 2022
Sponsor
Ruijin Hospital
Collaborators
Zhangjiagang Aoyang Hospital of Jiangsu Province
search

1. Study Identification

Unique Protocol Identification Number
NCT05485025
Brief Title
Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment
Acronym
TIPS
Official Title
Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment
Study Type
Interventional

2. Study Status

Record Verification Date
July 2022
Overall Recruitment Status
Not yet recruiting
Study Start Date
September 2022 (Anticipated)
Primary Completion Date
September 2026 (Anticipated)
Study Completion Date
September 2026 (Anticipated)

3. Sponsor/Collaborators

Responsible Party, by Official Title
Principal Investigator
Name of the Sponsor
Ruijin Hospital
Collaborators
Zhangjiagang Aoyang Hospital of Jiangsu Province

4. Oversight

Studies a U.S. FDA-regulated Drug Product
No
Studies a U.S. FDA-regulated Device Product
No
Data Monitoring Committee
Yes

5. Study Description

Brief Summary
This study evaluates the effects of 3 years-Tai Chi exercise intervention on cognitive function in subjects with subjective cognitive impairment (SCI). Participants will be randomized into the Tai chi training group and the control group.
Detailed Description
Dementia is a syndrome of impairments of cortical functions caused by brain diseases. More than 55 million people worldwide are currently living with dementia, with nearly 10 million new cases each year. Alzheimer's disease (AD) is the most common form of dementia and may account for 60-70% of patients with dementia. Mild cognitive impairment (MCI) is an intermediate state between normal cognitive aging and dementia. About 10% to 15% of patients with MCI progress to dementia each year. In recent years, studies have found that there is an earlier stage before MCI, that is, the stage of subjective cognitive impairment (SCI). SCI is a stage between normal aging and MCI, which is manifested by the self-reported experience of worsening or more frequent memory loss but not supported by objective evidence. Subjects with SCI are more likely to develop AD. According to the US CDC data, the prevalence of SCI among adults aged 65 years and older is 11.7%. Therefore, it is crucial to find intervention strategies to prevent the progression of SCI to MCI and dementia. However, drug interventions are currently ineffective in the prevention and treatment of such diseases. Based on the synaptic plasticity, more and more studies focus on non-drug interventions. Our research group previously found non-drug interventions (cognitive training, exercise therapy) can effectively delay cognitive decline in the elderly. Therefore, this project plans to conduct a multi-site, randomized, parallel-controlled clinical trial to examine the effect of 3 years-Tai Chi exercise intervention on cognitive function in SCI subjects and to provide a new clinical basis for the prevention and treatment of cognitive disorders.

6. Conditions and Keywords

Primary Disease or Condition Being Studied in the Trial, or the Focus of the Study
Subjective Cognitive Impairment
Keywords
subjective cognitive impairment, Tai Chi

7. Study Design

Primary Purpose
Prevention
Study Phase
Not Applicable
Interventional Study Model
Parallel Assignment
Masking
Outcomes Assessor
Allocation
Randomized
Enrollment
134 (Anticipated)

8. Arms, Groups, and Interventions

Arm Title
Tai chi training plus group activity
Arm Type
Experimental
Arm Description
Tai chi training: a teacher will give two 60-min lessons per week. Participants will play Tai Chi in the lessons, following teacher's instruction. Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
Arm Title
Only group activity
Arm Type
Experimental
Arm Description
Group activity: a organizer will lead the subjects to participate in group activities, once per quarter.
Intervention Type
Behavioral
Intervention Name(s)
Tai chi training
Intervention Description
Tai chi, also called tai chi chuan, is an ancient Chinese form of exercise originally created as a fighting art. It is a kind of gentle physical exercise and stretching, which involves a series of movements performed in a slow, focused manner and accompanied by deep breathing.
Intervention Type
Behavioral
Intervention Name(s)
Group activity
Intervention Description
A organizer will lead the subjects to participate in group activities once a quarter. In group activities, there will be popular science lectures and interactive games.
Primary Outcome Measure Information:
Title
The global cognitive function of SCI subjects.
Description
Repeatable Battery for the Assessment of Neuropsychological Status(RBANS) will be used to assess the global cognitive performance of SCI subjects.
Time Frame
36 months
Secondary Outcome Measure Information:
Title
Memory
Description
Memory will be assessed using the Auditory verbal learning test-Huashan version (AVLT-H).
Time Frame
18 months and 36 months
Title
Attention
Description
Attention will be evaluated by Trial Making Test (TMT).
Time Frame
18 months and 36 months
Title
Executive function
Description
Executive function will be evaluated by the Stroop task.
Time Frame
18 months and 36 months
Title
Language
Description
Language will be assessed by Boston naming test (30-item version), and Verbal Fluency.
Time Frame
18 months and 36 months
Title
Working memory test
Description
Working memory test will be assessed by Number Span Forward and Backward.
Time Frame
18 months and 36 months
Title
Visual spatial ability
Description
Visual spatial ability will be assessed by Clock Drawing Test.
Time Frame
18 months and 36 months
Title
Change from baseline in MoCA score
Description
Change from baseline in Montreal Cognitive Assessment (MoCA) score.
Time Frame
18 months and 36 months
Title
Change from baseline in CDR score
Description
Change from baseline in Clinical Dementia Rating (CDR) Scale score.
Time Frame
18 months and 36 months
Title
Activities of daily living
Description
Activities of daily living will be assessed by functional activities questionnaire (FAQ).
Time Frame
18 months and 36 months
Title
Anxiety
Description
Anxiety will be assessed by Hamilton Anxiety Rating Scale (HAMA).
Time Frame
18 months and 36 months
Title
Depression
Description
Depression will be assessed by Hamilton Depression Rating Scale (HAMD).
Time Frame
18 months and 36 months
Title
Sleep
Description
Sleep will be assessed by Pittsburgh Sleep Quality Index (PSQI).
Time Frame
18 months and 36 months
Title
Brain activity
Description
Detecting changes associated with blood flow by fMRI.
Time Frame
36 months
Title
Neurodegeneration in brain structures
Description
Brain atrophy will be assessed by Magnetic Resonance Volume Imaging.
Time Frame
36 months
Title
Gut microbiota
Description
Gut microbiota will be assessed by 16S rRNA sequencing.
Time Frame
18 months and 36 months
Title
Blood biomarkers
Description
Inflammatory factors (FGF basic、Eotaxin、G-CSF、GM-CSF、IFN-γ、IL-1β、IL-1ra、IL-2、IL-4、IL-5、IL-6、IL-7、IL-8、IL-9、IL-10、IL-12 (p70)、IL-13、IL-15、IL-17、IP-10、MCP-1 (MCAF)、MIP-1α、MIP-1β、PDGF-BB、RANTES、TNF-α、VEGF) will be measured by Bio-Plex Human Cytokine Assays. Nfl, Aβ40, Aβ42,T-tau, p-tau
Time Frame
18 months and 36 months
Title
Gait and Hand writing Task
Description
Using wearable sensors to assess gait and hand writing task.
Time Frame
18 months and 36 months
Title
Incidence of SCI converted to MCI and Alzheimer's disease.
Description
The 3-year incidence of MCI and AD in each group will be compared.
Time Frame
36 months

10. Eligibility

Sex
All
Minimum Age & Unit of Time
60 Years
Maximum Age & Unit of Time
75 Years
Accepts Healthy Volunteers
No
Eligibility Criteria
Inclusion Criteria: Male and female participants aged 60 to 75 years (inclusive) at the time of screening; Willing and able to give informed consent by GCP and local guidance; Meets the diagnostic criteria for subjective cognitive impairment (SCI) and the following criteria Subjective decline in memory, rather than other domains of cognition Onset of SCI within the last 5 y Concerns (worries) associated with SCI Feeling of worse performance than others of the same age group Confirmation of cognitive decline by an informant. Have the physical, cognitive, listening, speech, literacy and language skills necessary to participate in all tests; Capable of performing MR. Exclusion Criteria: Cognitive impairment caused by other reasons (for example) cerebrovascular disease, central nervous system infection, Creutzfeldt-Jakob disease, Huntington's disease, Parkinson's disease, dementia with Lewy bodies, trauma, other physical and chemical factors (drugs, alcohol, CO, etc.), important physical diseases (hepatic encephalopathy, pulmonary encephalopathy, etc.), brain tumor, endocrine diseases (thyroid disease, parathyroid disease), and vitamin deficiency or any other cause of dementia; Abnormal folate, thyroid, and/or vitamin B12 values that cannot be corrected before baseline visit; Major structural brain disease as judged by central MRI Diagnostic Imaging Review Team (eg, ischemic infarcts, subdural hematoma, hemorrhage, hydrocephalus, brain tumors, multiple subcortical ischemic lesions. or a single lesion in a critical region [eg, thalamus]). Mild white matter changes without clinical significance and no more than 2 lacunar infarcts are permitted; Geriatric Depression Scale-15(GDS-15) total score > 7 at screening; MOCA<26 points; CDR global score >0; Hachinski ischemia score >4; During the clinical study, the following drugs are prohibited: Acetylcholinesterase inhibitors, N-methyl-D-aspartate (NMDA) antagonists (eg, memantine), central nervous system stimulants, and various medicines that can improve memory or cognition; Antipsychotics Mental illness determined by Diagnostic and Statistical Manual of Mental Disorders (DSM) V criteria, that is unstable within 12 months, or would interfere with study assessments, including schizophrenia or other psychotic disorders, bipolar disorder, severe depression, or delirium. DSM V diagnosis of alcohol or other substance abuse dependence within the last 12 months. History or current diagnosis of significant cardiac arrhythmias, myocardial infarction, transient ischemic attack, or cerebrovascular accident, uncompensated congestive heart failure New York Heart Association class III and IV. Major medical illness or unstable medical condition within 6 months of screening that in the opinion of the investigator may interfere with the participant's ability to comply with study procedures and abide by study restrictions, or with the ability to interpret safety data, including any physical disability (eg. blindness. deafness, non-cognitive related speech impairment, sensory or motor dysfunction) that would prevent completion of study procedures or assessments. Cancer except: History of any cancer that has been in remission (no evidence of recurrence) for > 5 years from the screening Participants with basal cell or stage I squamous cell carcinoma of the skin, stable untreated cancer as prostate or meningioma. Active physical activity for 6 months prior to screening. Participants are excluded if they have participated in any other clinical study within 4 weeks prior to screening visit have participated in another Tai chi clinical study at any time plan to take part in another clinical study during this study. The researcher estimates that the subject's compliance is poor, and it is believed that the subject is unlikely to complete the study.
Facility Information:
Facility Name
Shanghai Jiao Tong University School of Medicine Affiliated Ruijin Hospital
City
Shanghai
Country
China
Facility Contact:
First Name & Middle Initial & Last Name & Degree
Shengdi Chen, Ph.D, MD
Phone
86-21-6445-4473
Email
chensd@rjh.com.cn
First Name & Middle Initial & Last Name & Degree
Chao Gao, Ph.D, MD
Phone
86-18217590273
Email
anshangaochao@163.com

12. IPD Sharing Statement

Plan to Share IPD
No

Learn more about this trial

Long Term Prospective Study of Tai Chi Intervention to Delay the Progression of Subjective Cognitive Impairment

We'll reach out to this number within 24 hrs